GeneDx Holdings Corp. (WGS) Stock Analysis
Healthcare · Diagnostics & Research · NasdaqGS
GeneDx Holdings Corp. (WGS) posted $427.54M in revenue for fiscal 2025 (up 40.0% year over year), with a net loss of $21.02M, and has compounded revenue about 19.0%/yr over five years, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on GeneDx Holdings Corp.
GeneDx Holdings Corp. has grown revenue from $196.17M to $427.54M over the last 7 fiscal years, compounding about 19% a year. The most recent year was up 40%, so growth is actually accelerating.
Net margin sits at -4.9%, up 12.2 points year over year on a 69.7% gross margin. It carries about $52.72M of total debt.
At today's valuation the market is pricing in roughly 32.4% annual free-cash-flow growth. The one thing worth a second look in the filings is receivables growing faster than sales.
Synthesised from GeneDx Holdings Corp.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
GeneDx Holdings Corp. revenue & earnings — last 7 fiscal years
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $196.17M | $179.32M | $212.19M | $234.69M | $202.57M | $305.45M | $427.54M |
| Gross profit | $82.78M | $4.03M | $-16.60M | $-26.75M | $90.01M | $194.40M | $298.17M |
| Net income | $-29.70M | $-241.34M | $-245.39M | $-548.98M | $-175.77M | $-52.29M | $-21.02M |
| Net margin | -15.1% | -134.6% | -115.6% | -233.9% | -86.8% | -17.1% | -4.9% |
Source: GeneDx Holdings Corp. SEC filings (10-K).
GeneDx Holdings Corp.: 2 potential red flags in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Receivables growing faster than salesAccounts receivable rose 97.6% while revenue rose 40.0% in the latest year — a gap that can signal looser credit terms or pulled-forward sales. Worth checking days-sales-outstanding.
- Currently unprofitableThe latest fiscal year was a net loss (net margin -4.9%).
What growth is priced into WGS stock?
At today's market cap of $1.69B, GeneDx Holdings Corp. is priced for free-cash-flow growth of about 32.4% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $14.26M from the FY ending 2025-12-31). For comparison, revenue 19%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 7 years of GeneDx Holdings Corp. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track WGS in your portfolio →
GeneDx Holdings Corp. financial history by metric
About GeneDx Holdings Corp.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
GeneDx Holdings Corp. — frequently asked questions
What is GeneDx Holdings Corp.'s revenue?
GeneDx Holdings Corp. (WGS) reported revenue of $427.54M for fiscal year 2025, up 40.0% from the prior year, according to its SEC filings.
Is GeneDx Holdings Corp. profitable?
No — WGS reported a net loss of $-21.02M in fiscal 2025.
What is WGS's P/E ratio?
GeneDx Holdings Corp. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is GeneDx Holdings Corp. growing?
WGS's revenue grew at roughly 19.0% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does GeneDx Holdings Corp. have?
As of fiscal year 2025, WGS carried roughly $52.72M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is GeneDx Holdings Corp.'s gross margin?
WGS's gross margin was 69.7% in fiscal 2025 — gross profit of $298.17M on revenue of $427.54M.
What is GeneDx Holdings Corp.'s market cap?
GeneDx Holdings Corp. (WGS) has a market capitalization of about $1.69B, based on the latest data in our nightly-refreshed cache.
When does GeneDx Holdings Corp.'s fiscal year end?
WGS's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into WGS stock?
At today's market cap of $1.69B, GeneDx Holdings Corp. is priced for free-cash-flow growth of about 32.4% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $14.26M from the FY ending 2025-12-31). For comparison, revenue 19%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from GeneDx Holdings Corp.'s official SEC filings (10-K and 10-Q), covering 7 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.